Month: May 2023

— First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million — — Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year — — Majority of aesthetic orders in the first quarter, or 54%, represented reorder activity — — Approximately 4,800 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the first quarter, a 12% increase from prior quarter end — — UPNEEQ Won “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards, selected from among 10,000 entrants — BRIDGEWATER, N.J., May 11, 2023 (GLOBE NEWSWIRE) — RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty...

– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and orphan designation from the EMA for SYNB1934 as a potential treatment for PKU – CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the first quarter ended March 31, 2023, and provided an update on its pipeline programs. “We continue to advance the SYNB1934 program towards initiation of our pivotal study, Synpheny-3, in the first half of the year, focused on our opportunity to transform the medical management of PKU,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive...

CALGARY, Alberta, May 11, 2023 (GLOBE NEWSWIRE) — Sylogist Ltd. (TSX: SYZ) (“Sylogist” or the “Company”), a leading public sector SaaS company, is pleased to announce its unaudited financial results for the three-month period ended on March 31, 2023. “Momentum is continuing, with our team delivering an exceptionally strong performance again in Q1, posting record quarterly revenue of $15.9M, including 21% organic growth and strong bookings,” commented Bill Wood, CEO. “We closed $7.7 million in bookings this quarter, reflecting accelerating strength in demand for our solutions from new logos and customer cross-sells alike; achieved by our platform vs. products strategy. We are also pleased with the 6% quarter-over-quarter increase in revenue per employee we saw, indicating increased utilization and delivery efficacy amongst our project...

Distributable Earnings Before Realizations up 24% to $4.3 billion over the last twelve months BROOKFIELD, NEWS, May 11, 2023 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) today announced financial results for the quarter ended March 31, 2023. Nick Goodman, President of Brookfield Corporation, stated, “Financial results in the first quarter were strong, supported by the growth and resilience of our businesses. The scale and quality of our franchise and our access to large and flexible capital allow us to thrive in periods of market volatility, and we expect to continue delivering on our broad growth initiatives in these markets. Above all, we remain focused on executing our plan to create long-term wealth for all of our stakeholders.” Operating Results Distributable earnings (“DE”) before realizations increased...

Revenue increased 3.5% to $466.4 million, compared to Q1 2022Gross margin decreased 0.2% to $144.5 million, compared to Q1 2022Net loss was $32.0 million, compared to net income of $25.3 million in Q1 2022Adjusted EBITDA decreased 25.0% to $28.5 million, compared to Q1 2022Affirms previously issued 2023 guidanceATLANTA, May 11, 2023 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings, Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three-month period ended April 1, 2023. Jeff Shaner, Chief Executive Officer, commented “Our first quarter results reflect the Aveanna team’s remarkable ability to adapt and transform our businesses as we execute on our strategic initiatives. Enhanced payor partnerships...

Q1 2023 Revenues and EPS Beat Guidance, Gross Margin Within Guidance Range Issued on February 9, 2023Company Q2 2023 Guidance: Revenues to Flat to Down 9.0% QoQ, IFRS Gross Margin is Expected to be 20.0% to 21.0%, IFRS Profit per basic ADS to be around -2.9 Cents to 0.6 Cents; Non-IFRS Profit per Diluted ADS to be around 0.1 Cents to 3.6 CentsQ1 2023 revenues were $244.2M, a decrease of 6.9% QoQ, markedly exceeding guidance of a decrease of around 12.0% to 17.0%. Q1 GM reached 28.1% Q1 2023 IFRS after-tax profit was $14.9M, or 8.5 cents per diluted ADS, compared to $42.2M, or 24.1 cents last quarter Company’s Q2 2023 revenues to flat to down 9.0% QoQ. GM around 20.0% to 21.0%. IFRS Profit per basic ADS to be in the range of -2.9 to 0.6 cents. Non-IFRS profit per diluted ADS to be in the range of 0.1 to 3.6 cents Company announced an...

~ Strong PEDMARK® Commercial Momentum Building in 2023 with Broad Payor and Medicaid Coverage ~ ~ PEDMARK® Permanent J-Code Effective April 1, 2023 ~ ~ Recent Positive CHMP Opinion in EU Recommending Approval of PEDMARQSI™ ~ ~ Company to Host Conference Call Today, Thursday, May 11 at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 11, 2023 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal quarter ended March 31, 2023 and provided a business update. “During the first quarter, we continued to see strong commercial momentum and uptake of PEDMARK®, further underscoring the significant unmet medical need that exists for pediatric solid tumor cancer patients at risk for developing hearing loss associated with cisplatin...